Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
Bruton’s tyrosine kinase (BTK) is a proven target in mantle cell lymphoma (MCL), an aggressive subtype of non-Hodgkin lymphoma. However, resistance to BTK inhibitors is a major clinical challenge. We here report that MALT1 is one of the top overexpressed genes in ibrutinib-resistant MCL cells, while...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society for Clinical Investigation
2023-02-01
|
| Serier: | The Journal of Clinical Investigation |
| Fag: | |
| Online adgang: | https://doi.org/10.1172/JCI165694 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
